Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planNo plan disclosedOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 8 of the 13 calendar months from Oct 2025 to Oct 2026: Mar 2026, Apr 2026, May 2026, Jun 2026, Jul 2026, Aug 2026, Sep 2026 and Oct 2026.
- Largest single sale: $1.6M (18,232 shares) of Spyre Therapeutics, Inc. on Sep 2, 2026. Filing
- Last sale before this period: Sep 2, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | Chief Financial Officer | Sep 5, 2023 | Oct 2, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Oct 1, 2026, Spyre Therapeutics, Inc.: sold 7,500 shares for $689K, under a disclosed plan; 7,500 shares acquired by exercising options. 1 filing: 1
- Sep 30, 2026, Spyre Therapeutics, Inc.: sold 17,500 shares for $1.6M, under a disclosed plan; 17,500 shares acquired by exercising options. 1 filing: 1
- Sep 2, 2026, Spyre Therapeutics, Inc.: sold 18,232 shares for $1.6M, under a disclosed plan. 1 filing: 1
- Sep 1, 2026, Spyre Therapeutics, Inc.: sold 7,500 shares for $655K, under a disclosed plan; 7,500 shares acquired by exercising options. 1 filing: 1
- Aug 3, 2026, Spyre Therapeutics, Inc.: sold 7,500 shares for $717K, under a disclosed plan; 7,500 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.